No data available.
No data available.
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | ZTS | Zoetis Inc. | 56.15 Bn | 21.18 | 5.98 | 7.27 Bn |
| 2 | TAK | Takeda Pharmaceutical Co Ltd | 48.92 Bn | 221.13 | 1.66 | 36.24 Bn |
| 3 | HLN | Haleon plc | 46.13 Bn | 25.59 | 3.29 | - |
| 4 | TEVA | Teva Pharmaceutical Industries Ltd | 35.27 Bn | 49.54 | 2.10 | 17.07 Bn |
| 5 | UTHR | UNITED THERAPEUTICS Corp | 21.76 Bn | 17.11 | 6.95 | 0.00 Bn |
| 6 | VTRS | Viatris Inc | 14.87 Bn | -4.03 | 1.05 | 14.44 Bn |
| 7 | NBIX | Neurocrine Biosciences Inc | 14.08 Bn | 32.91 | 5.25 | 0.43 Bn |
| 8 | ELAN | Elanco Animal Health Inc | 11.64 Bn | 323.29 | 2.54 | 4.32 Bn |
| Current Valuation | Value | Ind Avg | Percentile |
|---|---|---|---|
| EV to Assets EV to Assets | 0.15 | 24.98 | |
| EV to Cash from Ops. EV/CFO | -0.60 | -85.40 | |
| EV to Debt EV to Debt | 0.78 | 265.88 | |
| EV to EBIT EV/EBIT | -0.70 | -32.65 | |
| EV to EBITDA EV/EBITDA | -0.60 | -29.50 | |
| EV to Free Cash Flow [EV/FCF] EV/FCF | -0.60 | -32.62 | |
| EV to Market Cap EV to Market Cap | 0.29 | -10.98 | |
| EV to Revenue EV/Rev | 19.87 | -700.14 | |
| Price to Book Value [P/B] P/B | 0.71 | 27.22 | |
| Price to Earnings [P/E] P/E | -1.69 | -122.96 |
| Dividend Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio Dividend Coverage Ratio | 0.00 | 0.34 | |
| Dividend Payout Ratio % Dividend Payout Ratio % | 0.00 | 4.81 | |
| Dividend per Basic Share Div per Share (Qtr) | 0.00 | 0.07 | |
| FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) | 0.00 | 4.08 | |
| Interest Coverage Int. cover (Qtr) | -2.41 | -38.10 |
| Growth Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Capex Growth (1y) % Capex Growth (1y) % | 2.32 | -157.22 | |
| Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) | 1,286.97 | 44,776.25 | |
| Dividend Growth (1y) % Dividend Growth (1y) % | 0.00 | 2.81 | |
| EBIAT Growth (1y) % EBIAT 1y % (Qtr) | -57.27 | 24.45 | |
| EBITDA Growth (1y) % EBITDA 1y % (Qtr) | -84.09 | 18.14 | |
| EBIT Growth (1y) % EBIT 1y % (Qtr) | -57.27 | 37.66 | |
| EBT Growth (1y) % EBT 1y % (Qtr) | -84.93 | 108.18 | |
| EPS Growth (1y) % EPS Growth (1y) % | -61.48 | 52.88 | |
| FCF Growth (1y) % FCF 1y % (Qtr) | -407.82 | -54.47 | |
| Gross Profit Growth (1y) % Gross Profit Growth (1y) % | 0.00 | 25.28 |
| Liquidity Ratios | Value | Ind Avg | Percentile |
|---|---|---|---|
| Asset Utilization Ratio Asset Util Ratio (Qtr) | 0.01 | 0.50 | |
| Cash Payout Ratio Cash Payout (Qtr) | 0.00 | 0.02 | |
| Cash Ratio Cash Ratio (Qtr) | 0.06 | 2.10 | |
| Current Ratio Curr Ratio (Qtr) | 0.27 | 3.92 | |
| Debt to Equity Ratio Debt/Equity (Qtr) | 0.27 | -1.11 | |
| Interest Cover Ratio Int Coverage (Qtr) | -2.41 | -38.10 | |
| Times Interest Earned Times Interest Earned (Qtr) | -2.41 | -38.10 |
| Profitability | Value | Ind Avg | Percentile |
|---|---|---|---|
| EBITDA Margin % EBITDA Margin % | -2,834.30 | -62,432.09 | |
| EBIT Margin % EBIT Margin % | -4,308.13 | -63,260.88 | |
| EBT Margin % EBT Margin % | -4,011.86 | -66,726.96 | |
| Gross Margin % Gross Margin % | 30.30 | 8,332.72 | |
| Net Profit Margin % Net Profit Margin % | -4,011.90 | -66,728.37 |